个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH)

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Shao, Guoliang * ; Bai, Yuxian ; Chen, Xiaoming ; Gu, Shanzhi ; Gu, Kangsheng ; Yuan, Xianglin ; Widau, Ryan C. ; Zhang, Wanli ; Zhang, Qiang ; Qin, Shukui ;
单位： [1]Zhejiang Canc Hosp, Dept Radiol, Hangzhou, Peoples R China [2]Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China [3]Guangdong Prov Peoples Hosp, Dept Intervent Therapy, Guangzhou, Peoples R China [4]Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China [5]Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China [7]Eli Lilly & Co, Indianapolis, IN USA [8]Eli Lilly & Co, Shanghai, Peoples R China [9]Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
出处：
ISSN：
基金：
Eli Lilly and Company
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
推荐引用方式(GB/T 7714)：
Shao Guoliang,Bai Yuxian,Chen Xiaoming,et al.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH)[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):E16081-E16081.
APA：
Shao, Guoliang,Bai, Yuxian,Chen, Xiaoming,Gu, Shanzhi,Gu, Kangsheng...&Qin, Shukui.(2022).Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Shao, Guoliang,et al."Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH)".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022):E16081-E16081

资源点击量：428 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）